Ph+ ALL

Pipeline Programs

Companies

Clinical Trials

3 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Ascentage PharmaChina - Beijing

1 program

OlverembatinibPhase 3Small Molecule4 trials

Active Trials

NCT05594758Available

NCT06401603Recruiting30Est. Jan 2029

NCT06423911Recruiting285Est. Feb 2026

+1 more trials

Trial Timeline

Clinical trial activity over time

2023

2024

2025

2026

2027

2028

2029

Ascentage PharmaOlverembatinib

Clinical Trials (4)

Total enrollment: 665 patients across 4 trials

NCT06423911 Ascentage PharmaOlverembatinib

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Start: Feb 2024Est. completion: Feb 2026285 patients

Phase 3Recruiting

NCT06051409 Ascentage PharmaOlverembatinib

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Start: Aug 2023Est. completion: Jun 2029350 patients

Phase 3Recruiting

NCT06401603 Ascentage PharmaOlverembatinib

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Start: Aug 2024Est. completion: Jan 202930 patients

Phase 1Recruiting

NCT05594758 Ascentage PharmaOlverembatinib

Named Patient Program for Olverembatinib (HQP1351)

N/AAvailable

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

3 actively recruiting trials targeting 665 patients

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.